Matteo Pallocca, Ivan Molineris, Enrico Berrino, Benedetta Marcozzi, Martina Betti, Lauretta Levati, Stefania D'Atri, Chiara Menin, Gabriele Madonna, Paola Ghiorzo, Jenny Bulgarelli, Virgina Ferraresi, Tiziana Venesio, Monica Rodolfo, Licia Rivoltini, Luisa Lanfrancone, Paolo Antonio Ascierto, Luca Mazzarella, Pier Giuseppe Pelicci, Ruggero De Maria, Gennaro Ciliberto, Enzo Medico, Giandomenico Russo
BACKGROUND: The current therapeutic algorithm for Advanced Stage Melanoma comprises of alternating lines of Targeted and Immuno-therapy, mostly via Immune-Checkpoint blockade. While Comprehensive Genomic Profiling of solid tumours has been approved as a companion diagnostic, still no approved predictive biomarkers are available for Melanoma aside from BRAF mutations and the controversial Tumor Mutational Burden. This study presents the results of a Multi-Centre Observational Clinical Trial of Comprehensive Genomic Profiling on Target and Immuno-therapy treated advanced Melanoma...
January 6, 2024: Journal of Translational Medicine